EP1832603B1
(de)
|
2001-06-05 |
2010-02-03 |
CureVac GmbH |
Stabilisierte mRNA mit erhöhtem G/C-Gehalt, enkodierend für ein bakterielles Antigen sowie deren Verwendung
|
DE10162480A1
(de)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
Die Applikation von mRNA für den Einsatz als Therapeutikum gegen Tumorerkrankungen
|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
US9012219B2
(en)
|
2005-08-23 |
2015-04-21 |
The Trustees Of The University Of Pennsylvania |
RNA preparations comprising purified modified RNA for reprogramming cells
|
EP3611266B1
(en)
|
2005-08-23 |
2022-11-09 |
The Trustees of the University of Pennsylvania |
Rna containing modified nucleosides and methods of use thereof
|
US20070054873A1
(en)
*
|
2005-08-26 |
2007-03-08 |
Protiva Biotherapeutics, Inc. |
Glucocorticoid modulation of nucleic acid-mediated immune stimulation
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
CA2628300C
(en)
|
2005-11-02 |
2018-04-17 |
Protiva Biotherapeutics, Inc. |
Modified sirna molecules and uses thereof
|
US7915399B2
(en)
*
|
2006-06-09 |
2011-03-29 |
Protiva Biotherapeutics, Inc. |
Modified siRNA molecules and uses thereof
|
US9074205B2
(en)
*
|
2006-10-18 |
2015-07-07 |
Marina Biotech, Inc. |
Nicked or gapped nucleic acid molecules and uses thereof
|
DE102006051516A1
(de)
*
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Basen-)modifizierte RNA zur Expressionssteigerung eines Proteins
|
DE102007001370A1
(de)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-kodierte Antikörper
|
EP2121925A2
(en)
*
|
2007-03-02 |
2009-11-25 |
MDRNA, Inc. |
Nucleic acid compounds for inhibiting ras gene expression and uses thereof
|
WO2008109361A1
(en)
*
|
2007-03-02 |
2008-09-12 |
Mdrna, Inc, |
Nucleic acid compounds for inhibiting erbb family gene expression and uses thereof
|
JP2010519907A
(ja)
*
|
2007-03-02 |
2010-06-10 |
エムディーアールエヌエー,インコーポレイテッド |
Vegfファミリー遺伝子の発現を抑制するための核酸化合物およびその使用
|
WO2009046739A1
(en)
*
|
2007-10-09 |
2009-04-16 |
Curevac Gmbh |
Composition for treating prostate cancer (pca)
|
WO2009127230A1
(en)
*
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
WO2010088927A1
(en)
*
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
US20100273220A1
(en)
*
|
2009-04-22 |
2010-10-28 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long rna molecules
|
US10837020B2
(en)
|
2009-04-22 |
2020-11-17 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long RNA molecules
|
EP2451475A2
(en)
|
2009-07-06 |
2012-05-16 |
Novartis AG |
Self replicating rna molecules and uses thereof
|
DE102009050308A1
(de)
|
2009-10-22 |
2011-05-05 |
Ludwig-Maximilians-Universität München |
RNA mit einer Kombination aus unmodifizierten und modifizierten Nucleotiden zur Proteinexpression
|
BR112012002291A2
(pt)
*
|
2009-07-31 |
2016-11-29 |
Ethris Gmbh |
"polirribonucleotídeo com uma sequência que codifica uma proteína ou fragmento de proteína, implante, e, processo para a seleção de sequências de nucleotídeos"
|
WO2011026185A1
(en)
*
|
2009-09-04 |
2011-03-10 |
Murdoch Childrens Research Institute |
An assay for monitoring a neurological condition
|
PL3338765T3
(pl)
|
2009-12-01 |
2019-06-28 |
Translate Bio, Inc. |
Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych
|
SG10201408129XA
(en)
*
|
2009-12-07 |
2015-02-27 |
Univ Pennsylvania |
Rna preparations comprising purified modified rna for reprogramming cells
|
AU2015215938B2
(en)
*
|
2009-12-07 |
2018-01-18 |
The Trustees Of The University Of Pennsylvania |
RNA preparations comprising purified modified RNA for reprogramming cells
|
EP2338520A1
(de)
|
2009-12-21 |
2011-06-29 |
Ludwig Maximilians Universität |
Konjugat mit Zielfindungsligand und dessen Verwendung
|
US8802438B2
(en)
|
2010-04-16 |
2014-08-12 |
Children's Medical Center Corporation |
Compositions, kits, and methods for making induced pluripotent stem cells using synthetic modified RNAs
|
LT4005592T
(lt)
|
2010-07-06 |
2023-01-10 |
Glaxosmithkline Biologicals S.A. |
Viriono tipo tiekimo dalelės, skirtos savaime besireplikuojančioms rnr molekulėms
|
PT2590626E
(pt)
|
2010-07-06 |
2016-01-26 |
Glaxosmithkline Biolog Sa |
Lipossomas com lípidos que têm um valor de pka vantajoso para administração de arn
|
ES2646669T3
(es)
|
2010-07-06 |
2017-12-14 |
Glaxosmithkline Biologicals Sa |
Procedimientos de aumento de una respuesta inmunitaria mediante el suministro de ARN
|
PT2591114T
(pt)
|
2010-07-06 |
2016-08-02 |
Glaxosmithkline Biologicals Sa |
Imunização de mamíferos de grande porte com doses baixas de arn
|
EP3578205A1
(en)
|
2010-08-06 |
2019-12-11 |
ModernaTX, Inc. |
A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
EP4066857B1
(en)
|
2010-08-31 |
2022-12-21 |
GlaxoSmithKline Biologicals SA |
Pegylated liposomes for delivery of immunogen-encoding rna
|
NZ608972A
(en)
|
2010-10-01 |
2015-09-25 |
Moderna Therapeutics Inc |
Engineered nucleic acids and methods of use thereof
|
KR102162111B1
(ko)
|
2010-10-11 |
2020-10-07 |
노파르티스 아게 |
항원 전달 플랫폼
|
WO2012075040A2
(en)
|
2010-11-30 |
2012-06-07 |
Shire Human Genetic Therapies, Inc. |
mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
|
US8710200B2
(en)
|
2011-03-31 |
2014-04-29 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids encoding a modified erythropoietin and their expression
|
EP3460064B8
(en)
*
|
2011-04-03 |
2024-03-20 |
The General Hospital Corporation d/b/a Massachusetts General Hospital |
Efficient protein expression in vivo using modified rna (mod-rna)
|
BR112013029490A2
(pt)
*
|
2011-05-17 |
2019-09-24 |
Moderna Therapeutics Inc |
ácidos nucleicos projetados e métodos de uso dos mesmos para vertebrados não humanos
|
DK3892295T3
(da)
|
2011-05-24 |
2023-05-15 |
BioNTech SE |
Individualiserede vacciner mod cancer
|
KR20220025112A
(ko)
|
2011-06-08 |
2022-03-03 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Mrna 전달을 위한 지질 나노입자 조성물 및 방법
|
EP2729165B1
(en)
|
2011-07-06 |
2017-11-08 |
GlaxoSmithKline Biologicals SA |
Immunogenic combination compositions and uses thereof
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
CA2850624A1
(en)
|
2011-10-03 |
2013-04-11 |
Moderna Therapeutics, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
WO2013078199A2
(en)
*
|
2011-11-23 |
2013-05-30 |
Children's Medical Center Corporation |
Methods for enhanced in vivo delivery of synthetic, modified rnas
|
US8497124B2
(en)
|
2011-12-05 |
2013-07-30 |
Factor Bioscience Inc. |
Methods and products for reprogramming cells to a less differentiated state
|
AU2012347919B2
(en)
|
2011-12-05 |
2017-02-02 |
Factor Bioscience Inc. |
Methods and products for transfecting cells
|
EP3988537A1
(en)
|
2011-12-07 |
2022-04-27 |
Alnylam Pharmaceuticals, Inc. |
Biodegradable lipids for the delivery of active agents
|
CN110201187A
(zh)
*
|
2011-12-16 |
2019-09-06 |
现代泰克斯公司 |
经修饰的核苷、核苷酸和核酸组合物
|
US20130165504A1
(en)
*
|
2011-12-21 |
2013-06-27 |
modeRNA Therapeutics |
Methods of increasing the viability or longevity of an organ or organ explant
|
SI3421601T1
(sl)
|
2011-12-30 |
2020-03-31 |
Cellscript, Llc |
Izdelava in uporaba in vitro-sintetizirane ssRNA za uvajanje v celice sesalca, da se inducira biološki ali biokemijski učinek
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
BR112014023898A2
(pt)
*
|
2012-03-27 |
2017-07-11 |
Curevac Gmbh |
moléculas de ácido nucleico artificiais compreendendo 5''utr top
|
JP6185553B2
(ja)
|
2012-03-27 |
2017-08-23 |
キュアバック アーゲー |
タンパク質又はペプチドの発現を改善するための人工核酸分子
|
AU2013243952A1
(en)
|
2012-04-02 |
2014-10-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
CA2868391A1
(en)
|
2012-04-02 |
2013-10-10 |
Stephane Bancel |
Polynucleotides comprising n1-methyl-pseudouridine and methods for preparing the same
|
US10501513B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides for the production of oncology-related proteins and peptides
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US10501512B2
(en)
|
2012-04-02 |
2019-12-10 |
Modernatx, Inc. |
Modified polynucleotides
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
CA2876155C
(en)
|
2012-06-08 |
2022-12-13 |
Ethris Gmbh |
Pulmonary delivery of mrna to non-lung target cells
|
EA037448B1
(ru)
*
|
2012-06-08 |
2021-03-30 |
Этрис Гмбх |
Способ доставки в легкие терапевтической мрнк с pei и фармацевтическая композиция
|
US20150267192A1
(en)
|
2012-06-08 |
2015-09-24 |
Shire Human Genetic Therapies, Inc. |
Nuclease resistant polynucleotides and uses thereof
|
EP2885419A4
(en)
|
2012-08-14 |
2016-05-25 |
Moderna Therapeutics Inc |
ENZYMES AND POLYMERASES FOR RNA SYNTHESIS
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
AU2013312440A1
(en)
|
2012-09-07 |
2015-03-19 |
Genentech, Inc. |
Methods and compositions for producing induced hepatocytes
|
KR102596302B1
(ko)
|
2012-11-01 |
2023-11-01 |
팩터 바이오사이언스 인크. |
세포에서 단백질을 발현시키는 방법들과 생성물들
|
PT2922554T
(pt)
*
|
2012-11-26 |
2022-06-28 |
Modernatx Inc |
Arn modificado nas porções terminais
|
WO2014082729A1
(en)
|
2012-11-28 |
2014-06-05 |
Biontech Ag |
Individualized vaccines for cancer
|
EP2929035A1
(en)
*
|
2012-12-07 |
2015-10-14 |
Shire Human Genetic Therapies, Inc. |
Lipidic nanoparticles for mrna delivering
|
EP2931914A4
(en)
*
|
2012-12-13 |
2016-08-17 |
Moderna Therapeutics Inc |
MODIFIED POLYNUCLEOTIDES FOR CHANGING THE CELL PHENOTYPE
|
EP3434774A1
(en)
|
2013-01-17 |
2019-01-30 |
ModernaTX, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
US9193788B2
(en)
|
2013-02-08 |
2015-11-24 |
Novartis Ag |
Anti-IL-17A antibodies and their uses
|
US20140242154A1
(en)
|
2013-02-22 |
2014-08-28 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compounds, Compositions, Methods, and Kits Relating to Telomere Extension
|
US20160024181A1
(en)
*
|
2013-03-13 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
CA2904151C
(en)
*
|
2013-03-14 |
2023-09-12 |
Shire Human Genetic Therapies, Inc. |
Cftr mrna compositions and related methods and uses
|
US20160030527A1
(en)
*
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Compositions and Methods for Treatment of Stroke
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
DK2970955T3
(en)
|
2013-03-14 |
2019-02-11 |
Translate Bio Inc |
METHODS FOR CLEANING MESSENGER RNA
|
US20160032316A1
(en)
|
2013-03-14 |
2016-02-04 |
The Trustees Of The University Of Pennsylvania |
Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides
|
US9957515B2
(en)
|
2013-03-15 |
2018-05-01 |
Cibus Us Llc |
Methods and compositions for targeted gene modification
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
EP3578663A1
(en)
|
2013-03-15 |
2019-12-11 |
ModernaTX, Inc. |
Manufacturing methods for production of rna transcripts
|
WO2014152030A1
(en)
|
2013-03-15 |
2014-09-25 |
Moderna Therapeutics, Inc. |
Removal of dna fragments in mrna production process
|
WO2014144767A1
(en)
|
2013-03-15 |
2014-09-18 |
Moderna Therapeutics, Inc. |
Ion exchange purification of mrna
|
EP3578652B1
(en)
|
2013-03-15 |
2023-07-12 |
ModernaTX, Inc. |
Ribonucleic acid purification
|
DE102013005361A1
(de)
*
|
2013-03-28 |
2014-10-02 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
Polyribonucleotid
|
JP2016522679A
(ja)
|
2013-04-04 |
2016-08-04 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
CRISPR/Cas系を用いたゲノム編集の治療的使用
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
ES2746803T3
(es)
|
2013-05-15 |
2020-03-06 |
Robert Kruse |
Traducción intracelular de ARN circular
|
DK3013964T3
(da)
|
2013-06-28 |
2020-06-15 |
Ethris Gmbh |
Sammensætninger til indføring af rna i celler
|
PT3019619T
(pt)
|
2013-07-11 |
2021-11-11 |
Modernatx Inc |
Composições que compreendem polinucleótidos sintéticos que codificam proteínas relacionadas com crispr e sgarn sintéticos e métodos de utilização
|
CN105555955B
(zh)
|
2013-07-26 |
2020-06-16 |
京都府公立大学法人 |
成骨细胞和制备成骨细胞的方法
|
AU2014315287A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
US10385088B2
(en)
|
2013-10-02 |
2019-08-20 |
Modernatx, Inc. |
Polynucleotide molecules and uses thereof
|
US10323076B2
(en)
|
2013-10-03 |
2019-06-18 |
Modernatx, Inc. |
Polynucleotides encoding low density lipoprotein receptor
|
DE102013111099B4
(de)
|
2013-10-08 |
2023-11-30 |
Eberhard Karls Universität Tübingen Medizinische Fakultät |
Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA
|
EP4276176A3
(en)
|
2013-10-22 |
2024-01-10 |
Translate Bio, Inc. |
Mrna therapy for argininosuccinate synthetase deficiency
|
EP3060258A1
(en)
|
2013-10-22 |
2016-08-31 |
Shire Human Genetic Therapies, Inc. |
Mrna therapy for phenylketonuria
|
MX2016005238A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Formulaciones de lipidos para la administracion de acido ribonucleico mensajero.
|
WO2015065505A1
(en)
*
|
2013-10-29 |
2015-05-07 |
Duke University |
Use of cyp27a1 inhibitors, statin, or lxr antagonists alone or in combination with conventional therapy for the treatment of breast cancer
|
CA2925021A1
(en)
|
2013-11-01 |
2015-05-07 |
Curevac Ag |
Modified rna with decreased immunostimulatory properties
|
EP3542802A1
(en)
|
2013-11-01 |
2019-09-25 |
CureVac AG |
Modified rna with decreased immunostimulatory properties
|
US10801070B2
(en)
|
2013-11-25 |
2020-10-13 |
The Broad Institute, Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer
|
US11725237B2
(en)
|
2013-12-05 |
2023-08-15 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
EP3082760A1
(en)
|
2013-12-19 |
2016-10-26 |
Novartis AG |
LEPTIN mRNA COMPOSITIONS AND FORMULATIONS
|
CA2934073A1
(en)
|
2013-12-20 |
2015-06-25 |
The Broad Institute, Inc. |
Combination therapy with neoantigen vaccine
|
CA2927254C
(en)
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
US11254951B2
(en)
|
2014-12-30 |
2022-02-22 |
Curevac Ag |
Artificial nucleic acid molecules
|
RU2717986C2
(ru)
|
2013-12-30 |
2020-03-27 |
Куревак Аг |
Искусственные молекулы нуклеиновой кислоты
|
RU2020104969A
(ru)
|
2014-01-31 |
2020-03-13 |
Фэктор Байосайенс Инк. |
Способы и продукты для получения и доставки нуклеиновых кислот
|
JP6606088B2
(ja)
|
2014-02-24 |
2019-11-13 |
サンガモ セラピューティクス, インコーポレイテッド |
ヌクレアーゼ媒介性標的化組み込みのための方法および組成物
|
WO2015128030A1
(en)
|
2014-02-26 |
2015-09-03 |
Ethris Gmbh |
Compositions for gastrointestinal administration of rna
|
CA3208184A1
(en)
|
2014-03-14 |
2015-09-17 |
Cibus Us Llc |
Methods and compositions for increasing efficiency of targeted gene modification using oligonucleotide-mediated gene repair
|
CA2944128C
(en)
*
|
2014-04-01 |
2022-08-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Capped and uncapped rna molecules and block copolymers for intracellular delivery of rna
|
SG11201608798YA
(en)
|
2014-04-23 |
2016-11-29 |
Modernatx Inc |
Nucleic acid vaccines
|
MX2016013965A
(es)
|
2014-04-25 |
2017-01-09 |
Shire Human Genetic Therapies |
Metodos de purificacion de arn mensajero.
|
WO2015184256A2
(en)
|
2014-05-30 |
2015-12-03 |
Shire Human Genetic Therapies, Inc. |
Biodegradable lipids for delivery of nucleic acids
|
PL3155129T3
(pl)
|
2014-06-10 |
2019-09-30 |
Curevac Ag |
Sposób zwiększania wytwarzania RNA
|
GB201410693D0
(en)
|
2014-06-16 |
2014-07-30 |
Univ Southampton |
Splicing modulation
|
WO2015196128A2
(en)
|
2014-06-19 |
2015-12-23 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules and uses thereof
|
WO2015200465A1
(en)
|
2014-06-24 |
2015-12-30 |
Shire Human Genetic Therapies, Inc. |
Stereochemically enriched compositions for delivery of nucleic acids
|
EP3161001A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
EP3766916B1
(en)
|
2014-06-25 |
2022-09-28 |
Acuitas Therapeutics Inc. |
Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
US20170204152A1
(en)
|
2014-07-16 |
2017-07-20 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
EP3169335B8
(en)
|
2014-07-16 |
2019-10-09 |
ModernaTX, Inc. |
Circular polynucleotides
|
WO2016014846A1
(en)
*
|
2014-07-23 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of intrabodies
|
JP6841753B2
(ja)
|
2014-09-15 |
2021-03-10 |
ザ チルドレンズ メディカル センター コーポレーション |
ヒストンh3−リジントリメチル化を除去することによって体細胞核移入(scnt)効率を増加させるための方法および組成物
|
AU2015317370A1
(en)
|
2014-09-19 |
2017-03-23 |
Regeneron Pharmaceuticals, Inc. |
Chimeric antigen receptors
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
CA2963288A1
(en)
|
2014-10-03 |
2016-04-07 |
Cold Spring Harbor Laboratory |
Targeted augmentation of nuclear gene output
|
JP6728156B2
(ja)
|
2014-11-02 |
2020-07-22 |
アークトゥラス・セラピューティクス・インコーポレイテッドArcturus Therapeutics,Inc. |
メッセンジャーuna分子およびその使用
|
RU2020109343A
(ru)
|
2014-11-05 |
2020-03-17 |
Вояджер Терапьютикс, Инк. |
Полинуклеотиды aadc для лечения болезни паркинсона
|
WO2016077123A1
(en)
|
2014-11-10 |
2016-05-19 |
Moderna Therapeutics, Inc. |
Multiparametric nucleic acid optimization
|
WO2016077125A1
(en)
|
2014-11-10 |
2016-05-19 |
Moderna Therapeutics, Inc. |
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
|
DE202015010000U1
(de)
|
2014-12-12 |
2023-07-03 |
CureVac SE |
Artifizielle Nukleinsäuremoleküle für eine verbesserte Proteinexpression
|
EP3034539A1
(en)
|
2014-12-19 |
2016-06-22 |
Ethris GmbH |
Compositions for introducing nucleic acid into cells
|
EP3757211A1
(en)
|
2014-12-19 |
2020-12-30 |
The Broad Institute, Inc. |
Methods for profiling the t-cell-receptor repertoire
|
EP3234193B1
(en)
|
2014-12-19 |
2020-07-15 |
Massachusetts Institute of Technology |
Molecular biomarkers for cancer immunotherapy
|
WO2016128060A1
(en)
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
US11241505B2
(en)
|
2015-02-13 |
2022-02-08 |
Factor Bioscience Inc. |
Nucleic acid products and methods of administration thereof
|
AU2016253972B2
(en)
*
|
2015-04-27 |
2020-01-02 |
Acuitas Therapeutics Inc. |
Nucleoside-modified RNA for inducing an adaptive immune response
|
CN116196401A
(zh)
|
2015-05-20 |
2023-06-02 |
博德研究所 |
共有的新抗原
|
TWI750122B
(zh)
|
2015-06-09 |
2021-12-21 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
CN114085198A
(zh)
|
2015-06-29 |
2022-02-25 |
爱康泰生治疗公司 |
用于递送核酸的脂质和脂质纳米颗粒制剂
|
EP3317415B1
(en)
|
2015-06-30 |
2019-05-15 |
Ethris GmbH |
Utrs increasing the translation efficiency of rna molecules
|
WO2017011766A1
(en)
|
2015-07-16 |
2017-01-19 |
Cornell University |
Methods of enhancing translation ability of rna molecules treatments, and kits
|
US11364292B2
(en)
|
2015-07-21 |
2022-06-21 |
Modernatx, Inc. |
CHIKV RNA vaccines
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
WO2017049286A1
(en)
|
2015-09-17 |
2017-03-23 |
Moderna Therapeutics, Inc. |
Polynucleotides containing a morpholino linker
|
EP3359670B2
(en)
|
2015-10-05 |
2024-02-14 |
ModernaTX, Inc. |
Methods for therapeutic administration of messenger ribonucleic acid drugs
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
WO2017060731A1
(en)
|
2015-10-09 |
2017-04-13 |
University Of Southampton |
Modulation of gene expression and screening for deregulated protein expression
|
EP3362571A4
(en)
|
2015-10-13 |
2019-07-10 |
Duke University |
GENOMIC ENGINEERING WITH TYPE I CRISPRISMS IN EUKARYOTIC CELLS
|
EP4086269A1
(en)
|
2015-10-16 |
2022-11-09 |
ModernaTX, Inc. |
Mrna cap analogs with modified phosphate linkage
|
US20190225644A1
(en)
*
|
2015-10-16 |
2019-07-25 |
Modernatx, Inc. |
Mrna cap analogs and methods of mrna capping
|
WO2017066797A1
(en)
|
2015-10-16 |
2017-04-20 |
Modernatx, Inc. |
Trinucleotide mrna cap analogs
|
BR112018008051A2
(pt)
|
2015-10-22 |
2018-11-13 |
Modernatx Inc |
vacinas de ácido nucleico para vírus de varicella zoster (vzv)
|
EP3364981A4
(en)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS
|
EP3364950A4
(en)
|
2015-10-22 |
2019-10-23 |
ModernaTX, Inc. |
VACCINES AGAINST TROPICAL DISEASES
|
MD3718565T2
(ro)
|
2015-10-22 |
2022-09-30 |
Modernatx Inc |
Vaccinuri împotriva virusului respirator
|
LT3368507T
(lt)
|
2015-10-28 |
2023-03-10 |
Acuitas Therapeutics Inc. |
Nauji lipidai ir lipidų nanodalelių kompozicijos, skirtos nukleorūgščių tiekimui
|
WO2017100551A1
(en)
|
2015-12-09 |
2017-06-15 |
Alexion Pharmaceuticals, Inc. |
HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION
|
US20210108252A1
(en)
|
2015-12-09 |
2021-04-15 |
Novartis Ag |
Label-free analysis of rna capping efficiency using rnase h, probes and liquid chromatography/mass spectrometry
|
MA43415A
(fr)
*
|
2015-12-09 |
2018-10-17 |
Modernatx Inc |
Arnm modifié codant pour une uridine diphosphate glucuronosyltransférase et utilisations associées
|
JP7080172B2
(ja)
|
2015-12-10 |
2022-06-03 |
モデルナティエックス インコーポレイテッド |
治療薬の送達のための組成物及び方法
|
EP3390636B1
(en)
|
2015-12-14 |
2021-05-19 |
Cold Spring Harbor Laboratory |
Antisense oligomers for treatment of dravet syndrome
|
US11096956B2
(en)
|
2015-12-14 |
2021-08-24 |
Stoke Therapeutics, Inc. |
Antisense oligomers and uses thereof
|
MA43568A
(fr)
|
2015-12-17 |
2018-11-14 |
Modernatx Inc |
Polynucléotides codant pour la méthylmalonyl-coa mutase
|
US20210206818A1
(en)
*
|
2016-01-22 |
2021-07-08 |
Modernatx, Inc. |
Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
|
CN109072248A
(zh)
|
2016-02-09 |
2018-12-21 |
希博斯美国有限公司 |
采用寡核苷酸介导的基因修复提高靶向基因修饰的效率的方法和组合物
|
WO2017151623A1
(en)
|
2016-03-01 |
2017-09-08 |
Alexion Pharmaceuticals, Inc. |
Biodegradable activated polymers for therapeutic delivery
|
US11318197B2
(en)
|
2016-03-03 |
2022-05-03 |
Duke University |
Compositions and methods for inducing HIV-1 antibodies
|
WO2017152146A2
(en)
|
2016-03-03 |
2017-09-08 |
Duke University |
Compositions and methods for inducing hiv-1 antibodies
|
US11377656B2
(en)
*
|
2016-03-10 |
2022-07-05 |
Novartis Ag |
Chemically modified messenger RNA's
|
JP6959654B2
(ja)
|
2016-03-31 |
2021-11-02 |
エスリス ゲーエムベーハーethris GmbH |
新規の最小utr配列
|
WO2017173354A2
(en)
*
|
2016-04-01 |
2017-10-05 |
University Of Iowa Research Foundation |
METABOLICALLY STABILIZED DOUBLE STRANDED mRNA
|
EP3443001A4
(en)
|
2016-04-11 |
2020-04-29 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
US20190167811A1
(en)
|
2016-04-13 |
2019-06-06 |
Modernatx, Inc. |
Lipid compositions and their uses for intratumoral polynucleotide delivery
|
WO2017184590A1
(en)
|
2016-04-18 |
2017-10-26 |
The Broad Institute Inc. |
Improved hla epitope prediction
|
HUE061077T2
(hu)
|
2016-05-18 |
2023-05-28 |
Modernatx Inc |
Interleukin-12 (IL12) kódoló polinukleotidok és felhasználásuk
|
WO2017201342A1
(en)
|
2016-05-18 |
2017-11-23 |
Modernatx, Inc. |
Polynucleotides encoding jagged1 for the treatment of alagille syndrome
|
CN115837014A
(zh)
|
2016-05-18 |
2023-03-24 |
摩登纳特斯有限公司 |
编码松弛素的多核苷酸
|
EP3458108A4
(en)
*
|
2016-05-18 |
2020-04-22 |
ModernaTX, Inc. |
POLYNUCLEOTIDES FOR CODING THE TRANSMEMBRANE CONDUCTIVE REGULATOR OF CYSTIC FIBROSE FOR TREATING CYSTIC FIBROSE
|
KR102598120B1
(ko)
|
2016-06-03 |
2023-11-07 |
리제너론 파마슈티칼스 인코포레이티드 |
외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
|
KR101916652B1
(ko)
|
2016-06-29 |
2018-11-08 |
올릭스 주식회사 |
작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
|
US10927383B2
(en)
|
2016-06-30 |
2021-02-23 |
Ethris Gmbh |
Cas9 mRNAs
|
AU2017293931A1
(en)
|
2016-07-07 |
2019-01-17 |
Rubius Therapeutics, Inc. |
Compositions and methods related to therapeutic cell systems expressing exogenous RNA
|
CN109803977B
(zh)
|
2016-08-17 |
2023-03-17 |
菲克特生物科学股份有限公司 |
核酸产品及其施用方法
|
AU2017326423B2
(en)
|
2016-09-14 |
2023-11-09 |
Modernatx, Inc. |
High purity RNA compositions and methods for preparation thereof
|
EP3519428A4
(en)
|
2016-10-03 |
2020-07-08 |
Duke University |
METHOD FOR IDENTIFYING IMMUNOGENIC BY TARGETING UNLIKIBLE MUTATIONS
|
SG10201914029RA
(en)
|
2016-10-14 |
2020-03-30 |
Precision Biosciences Inc |
Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome
|
AU2017345766A1
(en)
|
2016-10-21 |
2019-05-16 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
ES2917000T3
(es)
|
2016-10-24 |
2022-07-06 |
Orionis Biosciences BV |
Interferón-gamma mutante diana y usos del mismo
|
EP3532097A1
(en)
|
2016-10-27 |
2019-09-04 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified rna for inducing an adaptive immune response
|
WO2018081788A1
(en)
|
2016-10-31 |
2018-05-03 |
Cornell University |
Methods of enhancing translation ability and stability of rna molecules, treatments, and kits
|
EP3538068A1
(en)
|
2016-11-10 |
2019-09-18 |
Translate Bio, Inc. |
Improved ice-based lipid nanoparticle formulation for delivery of mrna
|
US10925958B2
(en)
|
2016-11-11 |
2021-02-23 |
Modernatx, Inc. |
Influenza vaccine
|
US11384352B2
(en)
|
2016-12-13 |
2022-07-12 |
Modernatx, Inc. |
RNA affinity purification
|
JP7317715B2
(ja)
|
2017-01-11 |
2023-07-31 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
ジカウイルスに対する免疫応答を誘導するためのヌクレオシド改変rna
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
EP3574019A4
(en)
|
2017-01-26 |
2021-03-03 |
Surrozen, Inc. |
TISSUE SPECIFIC, WNT SIGNAL REINFORCEMENT MOLECULES AND USES THEREOF
|
KR20190110612A
(ko)
|
2017-02-01 |
2019-09-30 |
모더나티엑스, 인크. |
활성화 종양유전자 돌연변이 펩티드를 인코드하는 면역조절 치료 mrna 조성물
|
WO2018144999A1
(en)
|
2017-02-06 |
2018-08-09 |
Orionis Biosciences, Inc. |
Targeted engineered interferon and uses thereof
|
EP3577133A1
(en)
|
2017-02-06 |
2019-12-11 |
Orionis Biosciences NV |
Targeted chimeric proteins and uses thereof
|
WO2018146557A2
(en)
*
|
2017-02-10 |
2018-08-16 |
Dong Ki Lee |
Long double-stranded rna for rna interference
|
WO2018157154A2
(en)
|
2017-02-27 |
2018-08-30 |
Translate Bio, Inc. |
Novel codon-optimized cftr mrna
|
IL268892B1
(en)
|
2017-02-27 |
2024-03-01 |
Translate Bio Inc |
Large-scale production of therapeutic preparations enriched in mRNA encoding therapeutic peptides
|
CA3054733A1
(en)
|
2017-02-28 |
2018-09-07 |
Sanofi |
Therapeutic rna
|
WO2018160592A1
(en)
*
|
2017-02-28 |
2018-09-07 |
Arcturus Therapeutics, Inc. |
Translatable molecules and synthesis thereof
|
US11464848B2
(en)
|
2017-03-15 |
2022-10-11 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
US11752206B2
(en)
|
2017-03-15 |
2023-09-12 |
Modernatx, Inc. |
Herpes simplex virus vaccine
|
WO2018170270A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Varicella zoster virus (vzv) vaccine
|
US11576961B2
(en)
|
2017-03-15 |
2023-02-14 |
Modernatx, Inc. |
Broad spectrum influenza virus vaccine
|
WO2018170347A1
(en)
|
2017-03-17 |
2018-09-20 |
Modernatx, Inc. |
Zoonotic disease rna vaccines
|
US11905525B2
(en)
|
2017-04-05 |
2024-02-20 |
Modernatx, Inc. |
Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
|
WO2018188730A1
(en)
*
|
2017-04-11 |
2018-10-18 |
Biontech Rna Pharmaceuticals Gmbh |
Rna for treatment of autoimmune diseases
|
WO2018191657A1
(en)
|
2017-04-13 |
2018-10-18 |
Acuitas Therapeutics, Inc. |
Lipids for delivery of active agents
|
US11660332B2
(en)
|
2017-04-27 |
2023-05-30 |
The Trustees Of The University Of Pennsylvania |
Nucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus
|
CN116693411A
(zh)
|
2017-04-28 |
2023-09-05 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
US11504421B2
(en)
|
2017-05-08 |
2022-11-22 |
Gritstone Bio, Inc. |
Alphavirus neoantigen vectors
|
IL270631B2
(en)
|
2017-05-16 |
2024-03-01 |
Translate Bio Inc |
Treatment of cystic fibrosis through the administration of mRNA with an optimal codon encoding ctfr
|
CA3063907A1
(en)
|
2017-05-31 |
2018-12-06 |
Ultragenyx Pharmaceutical Inc. |
Therapeutics for glycogen storage disease type iii
|
KR20200015932A
(ko)
|
2017-06-07 |
2020-02-13 |
리제너론 파마슈티칼스 인코포레이티드 |
효소 내재화를 위한 조성물 및 방법
|
US20200131498A1
(en)
|
2017-06-14 |
2020-04-30 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase
|
MA49395A
(fr)
*
|
2017-06-14 |
2020-04-22 |
Modernatx Inc |
Polynucléotides codant pour le facteur viii de coagulation
|
EP3638215A4
(en)
|
2017-06-15 |
2021-03-24 |
Modernatx, Inc. |
RNA FORMULATIONS
|
JOP20190269A1
(ar)
|
2017-06-15 |
2019-11-20 |
Voyager Therapeutics Inc |
بولي نوكليوتيدات aadc لعلاج مرض باركنسون
|
US10034951B1
(en)
|
2017-06-21 |
2018-07-31 |
New England Biolabs, Inc. |
Use of thermostable RNA polymerases to produce RNAs having reduced immunogenicity
|
JP2020530980A
(ja)
*
|
2017-07-04 |
2020-11-05 |
キュアバック アーゲー |
新規核酸分子
|
US11628227B2
(en)
*
|
2017-07-05 |
2023-04-18 |
Wisconsin Alumni Research Foundation |
Mineral coated microparticles for gene delivery in chronic wound therapy
|
EP3655040A1
(en)
|
2017-07-21 |
2020-05-27 |
Modernatx, Inc. |
Modified mrna encoding a propionyl-coa carboxylase and uses thereof
|
MA49684A
(fr)
|
2017-07-24 |
2020-06-03 |
Modernatx Inc |
Arnm modifié codant une glucose-6-phosphatase et utilisations associées
|
WO2019036008A1
(en)
|
2017-08-16 |
2019-02-21 |
Acuitas Therapeutics, Inc. |
LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS
|
JP7386535B2
(ja)
|
2017-08-17 |
2023-11-27 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
単純ヘルペスウイルス糖タンパク質をコードする修飾mRNAワクチン及びその使用
|
US11542225B2
(en)
|
2017-08-17 |
2023-01-03 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
US11524932B2
(en)
|
2017-08-17 |
2022-12-13 |
Acuitas Therapeutics, Inc. |
Lipids for use in lipid nanoparticle formulations
|
EP3668977A4
(en)
|
2017-08-18 |
2021-04-21 |
Modernatx, Inc. |
HPLC ANALYTICAL PROCESSES
|
CN111212905A
(zh)
|
2017-08-18 |
2020-05-29 |
摩登纳特斯有限公司 |
Rna聚合酶变体
|
WO2019036685A1
(en)
|
2017-08-18 |
2019-02-21 |
Modernatx, Inc. |
METHODS FOR HPLC ANALYSIS
|
PT3673080T
(pt)
|
2017-08-25 |
2023-12-06 |
Stoke Therapeutics Inc |
Oligómeros anti-sentido para o tratamento de estados patológicos e outras doenças
|
WO2019046809A1
(en)
|
2017-08-31 |
2019-03-07 |
Modernatx, Inc. |
METHODS OF MANUFACTURING LIPID NANOPARTICLES
|
EP3681514A4
(en)
|
2017-09-14 |
2021-07-14 |
ModernaTX, Inc. |
RNA VACZINE AGAINST ZIKA VIRUS
|
WO2019070730A1
(en)
|
2017-10-02 |
2019-04-11 |
Duke University |
MOSAIC ENVELOPES OF HIV-1 TO INDUCE ADCC RESPONSES
|
EP3704245A1
(en)
|
2017-11-01 |
2020-09-09 |
Novartis AG |
Synthetic rnas and methods of use
|
MA50801A
(fr)
|
2017-11-22 |
2020-09-30 |
Modernatx Inc |
Polynucléotides codant pour la phénylalanine hydroxylase pour le traitement de la phénylcétonurie
|
EP3714048A1
(en)
|
2017-11-22 |
2020-09-30 |
Modernatx, Inc. |
Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders
|
EP3724355A1
(en)
|
2017-12-15 |
2020-10-21 |
Novartis AG |
Polya tail length analysis of rna by mass spectrometry
|
KR20200118029A
(ko)
|
2018-01-04 |
2020-10-14 |
아이코닉 테라퓨틱스, 인코포레이티드 |
항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
|
US11359208B2
(en)
|
2018-01-09 |
2022-06-14 |
Cibus Us Llc |
Shatterproof genes and mutations
|
EP3746090A4
(en)
|
2018-01-29 |
2021-11-17 |
ModernaTX, Inc. |
RSV RNA Vaccines
|
EP3749295A4
(en)
|
2018-02-05 |
2022-04-27 |
Orionis Biosciences, Inc. |
FIBROBLAST BINDING AGENTS AND USES THEREOF
|
EP3749373A1
(en)
|
2018-02-07 |
2020-12-16 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for therapeutic protein delivery
|
EP3752610A1
(en)
|
2018-02-13 |
2020-12-23 |
ethris GmbH |
Polyribonucleotide containing deuterated nucleotides
|
MX2020009491A
(es)
*
|
2018-03-13 |
2020-10-28 |
Univ Leland Stanford Junior |
Reprogramacion celular transitoria para revertir el envejecimiento celular.
|
US11142750B2
(en)
|
2018-04-12 |
2021-10-12 |
Precision Biosciences, Inc. |
Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome
|
ES2955408T3
(es)
|
2018-04-12 |
2023-11-30 |
Prec Biosciences Inc |
Nucleasas modificadas genéticamente optimizadas que tienen especificidad para el gen de la región constante alfa del receptor de linfocitos t humanos
|
KR20210021943A
(ko)
|
2018-04-25 |
2021-03-02 |
에트리스 게엠베하 |
미립자 제형용 동결 방지제
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
CN108956566B
(zh)
*
|
2018-07-06 |
2020-10-02 |
军事科学院军事医学研究院环境医学与作业医学研究所 |
基于切刻内切酶和杂交链式反应双重放大的上转换荧光检测多氯联苯试剂盒及检测方法
|
EP3841208A1
(en)
|
2018-08-24 |
2021-06-30 |
Translate Bio, Inc. |
Methods for purification of messenger rna
|
US20220054653A1
(en)
*
|
2018-09-13 |
2022-02-24 |
Modernatx, Inc. |
Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
|
JP2022500436A
(ja)
*
|
2018-09-13 |
2022-01-04 |
モダーナティエックス・インコーポレイテッドModernaTX, Inc. |
糖原病を処置するためのグルコース−6−ホスファターゼをコードするポリヌクレオチド
|
EP3856233A1
(en)
*
|
2018-09-27 |
2021-08-04 |
Modernatx, Inc. |
Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
|
WO2020072700A1
(en)
|
2018-10-02 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Hla single allele lines
|
US20210386788A1
(en)
|
2018-10-24 |
2021-12-16 |
Obsidian Therapeutics, Inc. |
Er tunable protein regulation
|
WO2020118115A1
(en)
|
2018-12-06 |
2020-06-11 |
Arcturus Therapeutics, Inc. |
Compositions and methods for treating ornithine transcarbamylase deficiency
|
CN111303283A
(zh)
|
2018-12-12 |
2020-06-19 |
上海君实生物医药科技股份有限公司 |
抗il-17a抗体及其应用
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
EP3898661A1
(en)
|
2018-12-21 |
2021-10-27 |
Precision BioSciences, Inc. |
Genetic modification of the hydroxyacid oxidase 1 gene for treatment of primary hyperoxaluria
|
KR20210138569A
(ko)
|
2019-01-11 |
2021-11-19 |
아퀴타스 테라퓨틱스 인크. |
활성제의 지질 나노입자 전달을 위한 지질
|
US20220098621A1
(en)
|
2019-02-05 |
2022-03-31 |
Emendobio Inc. |
Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene
|
WO2020168466A1
(en)
|
2019-02-19 |
2020-08-27 |
Stemirna Therapeutics Co., Ltd. |
Modified nucleoside and synthetic methods thereof
|
AU2020224103A1
(en)
|
2019-02-20 |
2021-09-16 |
Modernatx, Inc. |
Rna polymerase variants for co-transcriptional capping
|
US11851694B1
(en)
|
2019-02-20 |
2023-12-26 |
Modernatx, Inc. |
High fidelity in vitro transcription
|
WO2020198403A2
(en)
*
|
2019-03-25 |
2020-10-01 |
Flagship Pioneering Innovations Vi, Llc |
Compositions comprising modified circular polyribonucleotides and uses thereof
|
EP4332115A2
(en)
|
2019-04-03 |
2024-03-06 |
Precision Biosciences, Inc. |
Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir)
|
EP3947646A1
(en)
|
2019-04-05 |
2022-02-09 |
Precision BioSciences, Inc. |
Methods of preparing populations of genetically-modified immune cells
|
US20230190819A1
(en)
*
|
2019-05-11 |
2023-06-22 |
Youngsuk Yi |
Compositions and methods containing exosomes
|
MX2021014525A
(es)
|
2019-05-30 |
2022-03-17 |
Gritstone Bio Inc |
Adenovirus modificados.
|
EP4001308A4
(en)
|
2019-07-15 |
2023-08-23 |
Shanghai Junshi Biosciences Co., Ltd. |
ANTI-TIGIT ANTIBODIES AND THEIR APPLICATION
|
US20220273715A1
(en)
|
2019-07-25 |
2022-09-01 |
Precision Biosciences, Inc. |
Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
|
US10501404B1
(en)
|
2019-07-30 |
2019-12-10 |
Factor Bioscience Inc. |
Cationic lipids and transfection methods
|
CA3149642A1
(en)
|
2019-08-09 |
2021-02-18 |
Nutcracker Therapeutics, Inc. |
Microfluidic apparatus and methods of use thereof
|
CN112390838A
(zh)
*
|
2019-08-14 |
2021-02-23 |
斯微(上海)生物科技有限公司 |
一种改性核苷及其合成方法
|
DE102019122014A1
(de)
|
2019-08-15 |
2021-02-18 |
Technische Universität Darmstadt |
Reduktion der Knochenresorption, insbesondere bei chronischen Gelenkerkrankungen
|
JP2022544825A
(ja)
|
2019-08-20 |
2022-10-21 |
プレシジョン バイオサイエンシズ,インク. |
細胞免疫療法のためのリンパ球枯渇投与レジメン
|
EP4031662A1
(en)
|
2019-09-20 |
2022-07-27 |
Translate Bio, Inc. |
Mrna encoding engineered cftr
|
JP2022552286A
(ja)
|
2019-10-09 |
2022-12-15 |
トランスレイト バイオ, インコーポレイテッド |
メッセンジャーrnaの組成物、方法および使用
|
EP4048316A1
(en)
|
2019-10-21 |
2022-08-31 |
Translate Bio, Inc. |
Compositions, methods and uses of messenger rna
|
BR112022006534A2
(pt)
|
2019-10-24 |
2022-07-05 |
Novago Therapeutics Ag |
Anticorpos anti-nogo-a
|
WO2021087305A1
(en)
|
2019-10-30 |
2021-05-06 |
Precision Biosciences, Inc. |
Cd20 chimeric antigen receptors and methods of use for immunotherapy
|
CN116057068A
(zh)
|
2019-12-06 |
2023-05-02 |
精密生物科学公司 |
对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶
|
EP4069285A1
(en)
|
2019-12-06 |
2022-10-12 |
Precision BioSciences, Inc. |
Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells
|
CN115461042A
(zh)
|
2019-12-20 |
2022-12-09 |
翻译生物公司 |
制备负载mrna的脂质纳米颗粒的改进方法
|
WO2021127394A2
(en)
|
2019-12-20 |
2021-06-24 |
Translate Bio, Inc. |
Rectal delivery of messenger rna
|
EP4085130A4
(en)
|
2019-12-31 |
2024-04-10 |
Elixirgen Therapeutics Inc |
TEMPERATURE-BASED TRANSIENT DELIVERY OF NUCLEIC ACIDS AND PROTEINS TO CELLS AND TISSUES
|
WO2021142245A1
(en)
|
2020-01-10 |
2021-07-15 |
Translate Bio, Inc. |
Compounds, pharmaceutical compositions and methods for modulating expression of muc5b in lung cells and tissues
|
US11576966B2
(en)
|
2020-02-04 |
2023-02-14 |
CureVac SE |
Coronavirus vaccine
|
CA3170319A1
(en)
|
2020-02-10 |
2021-08-19 |
Translate Bio, Inc. |
Methods and compositions for messenger rna purification
|
KR20220162125A
(ko)
|
2020-02-18 |
2022-12-07 |
트랜슬레이트 바이오 인코포레이티드 |
전령 rna의 시험관 내 전사를 위한 개선된 프로세스
|
CA3168749A1
(en)
|
2020-02-24 |
2021-09-02 |
Jinghua YAN |
Human monoclonal antibody of novel coronavirus and use thereof
|
CA3173035A1
(en)
|
2020-02-25 |
2021-09-02 |
Translate Bio, Inc. |
Improved processes of preparing mrna-loaded lipid nanoparticles
|
WO2021205077A1
(en)
|
2020-04-09 |
2021-10-14 |
Finncure Oy |
Mimetic nanoparticles for preventing the spreading and lowering the infection rate of novel coronaviruses
|
CN115811986A
(zh)
|
2020-04-22 |
2023-03-17 |
生物技术欧洲股份公司 |
冠状病毒疫苗
|
WO2021226463A1
(en)
|
2020-05-07 |
2021-11-11 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
CA3177940A1
(en)
|
2020-05-07 |
2021-11-11 |
Anusha DIAS |
Optimized nucleotide sequences encoding sars-cov-2 antigens
|
EP4147243A1
(en)
|
2020-05-07 |
2023-03-15 |
Translate Bio, Inc. |
Generation of optimized nucleotide sequences
|
EP4146342A1
(en)
|
2020-05-07 |
2023-03-15 |
Translate Bio, Inc. |
Improved compositions for cftr mrna therapy
|
WO2021231259A1
(en)
|
2020-05-11 |
2021-11-18 |
Precision Biosciences, Inc. |
Self-limiting viral vectors encoding nucleases
|
IL298063A
(en)
|
2020-05-11 |
2023-01-01 |
Stoke Therapeutics Inc |
opa1 antisense oligomers for the treatment of conditions and diseases
|
WO2021231495A1
(en)
|
2020-05-12 |
2021-11-18 |
Precision Biosciences, Inc. |
Treatment of retinitis pigmentosa using improved engineered meganucleases
|
CA3183399A1
(en)
|
2020-05-15 |
2021-11-18 |
Translate Bio, Inc. |
Lipid nanoparticle formulations for mrna delivery
|
US20230242624A1
(en)
|
2020-06-02 |
2023-08-03 |
Neurimmune Ag |
HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
|
JP2023534683A
(ja)
|
2020-07-13 |
2023-08-10 |
上海君▲実▼生物医▲薬▼科技股▲分▼有限公司 |
抗cldn-18.2抗体及びその用途
|
WO2022015513A2
(en)
|
2020-07-13 |
2022-01-20 |
The Board Of Trustees Of The Leland Stanford Junior University |
Systems and methods to assess rna stability
|
BR112023000327A2
(pt)
|
2020-07-16 |
2023-01-31 |
Acuitas Therapeutics Inc |
Lipídeos catiônicos para o uso em nanopartículas lipídicas
|
US20230295301A1
(en)
|
2020-07-21 |
2023-09-21 |
Shanghai Junshi Biosciences Co., Ltd. |
Anti-ctla-4 antibody and use thereof
|
BR112023002150A2
(pt)
|
2020-08-05 |
2023-05-02 |
Dragonfly Therapeutics Inc |
Anticorpos direcionando egfr e uso dos mesmos
|
IL300026A
(en)
|
2020-08-06 |
2023-03-01 |
Gritstone Bio Inc |
Multiepitope vaccine cassettes
|
WO2022035793A1
(en)
|
2020-08-10 |
2022-02-17 |
Precision Biosciences, Inc. |
Antibodies and fragments specific for b-cell maturation antigen and uses thereof
|
AU2021329403A1
(en)
|
2020-08-21 |
2023-05-04 |
Precision Biosciences, Inc. |
Engineered meganucleases having specificity for a recognition sequence in the transthyretin gene
|
US11406703B2
(en)
|
2020-08-25 |
2022-08-09 |
Modernatx, Inc. |
Human cytomegalovirus vaccine
|
EP4204015A2
(en)
|
2020-08-31 |
2023-07-05 |
The Board of Trustees of the Leland Stanford Junior University |
Systems and methods for producing rna constructs with increased translation and stability
|
AU2021358777A1
(en)
|
2020-10-06 |
2023-06-15 |
Translate Bio, Inc. |
Improved process and formulation of lipid nanoparticles
|
WO2022076547A1
(en)
|
2020-10-07 |
2022-04-14 |
Precision Biosciences, Inc. |
Lipid nanoparticle compositions
|
WO2022081548A1
(en)
|
2020-10-12 |
2022-04-21 |
Translate Bio, Inc. |
Improved process of preparing ice-based lipid nanoparticles
|
JP2023545128A
(ja)
|
2020-10-12 |
2023-10-26 |
トランスレイト バイオ, インコーポレイテッド |
mRNA搭載脂質ナノ粒子を製造する改善された方法
|
MX2023004299A
(es)
*
|
2020-10-13 |
2023-07-07 |
Univ Pennsylvania |
Direccionamiento de células t cd4+ in vivo para terapeuticos de arnm.
|
WO2022082001A1
(en)
|
2020-10-15 |
2022-04-21 |
Translate Bio, Inc. |
Large scale synthesis of messenger rna
|
WO2022090752A1
(en)
|
2020-10-26 |
2022-05-05 |
Pécsi Tudományegyetem |
Vaccine platform
|
EP4240326A1
(en)
|
2020-11-09 |
2023-09-13 |
Translate Bio, Inc. |
Improved compositions for delivery of codon-optimized mrna
|
GB202017649D0
(en)
|
2020-11-09 |
2020-12-23 |
Autolus Ltd |
Polypeptide
|
EP4244342A1
(en)
|
2020-11-12 |
2023-09-20 |
Precision BioSciences, Inc. |
Engineered meganucleases having specificity for recognition sequences in the dystrophin gene
|
WO2022106860A1
(en)
|
2020-11-20 |
2022-05-27 |
Pécsi Tudományegyetem |
Recombinant peptides for use in therapy
|
CN116723829A
(zh)
|
2020-11-25 |
2023-09-08 |
翻译生物公司 |
稳定的液体脂质纳米颗粒配制品
|
CN117098541A
(zh)
|
2020-11-25 |
2023-11-21 |
阿卡格拉医药公司 |
用于递送核酸的脂质纳米粒及相关使用方法
|
KR20230164648A
(ko)
|
2020-12-22 |
2023-12-04 |
큐어백 에스이 |
SARS-CoV-2 변이체에 대한 RNA 백신
|
EP4274889A1
(en)
|
2021-01-08 |
2023-11-15 |
Precision BioSciences, Inc. |
Engineered meganucleases having specificity for a recognition sequence in the hydroxyacid oxidase 1 gene
|
EP4277929A1
(en)
|
2021-01-14 |
2023-11-22 |
Translate Bio, Inc. |
Methods and compositions for delivering mrna coded antibodies
|
EP4284823A1
(en)
|
2021-01-28 |
2023-12-06 |
Precision BioSciences, Inc. |
Modulation of tgf beta signaling in genetically-modified eukaryotic cells
|
CA3209779A1
(en)
|
2021-02-01 |
2022-08-04 |
Regenxbio Inc. |
Gene therapy for neuronal ceroid lipofuscinoses
|
WO2022171080A1
(zh)
|
2021-02-09 |
2022-08-18 |
上海君实生物医药科技股份有限公司 |
抗cd112r抗体及其用途
|
WO2022177597A1
(en)
*
|
2021-02-16 |
2022-08-25 |
The Board Of Trustees Of The Leland Stanford Junior University |
Systems and methods to enhance rna stability and translation and uses thereof
|
CA3208070A1
(en)
|
2021-03-01 |
2022-09-09 |
Matthias Schneider |
Humanized antibodies against irhom2
|
US20220323553A1
(en)
*
|
2021-03-08 |
2022-10-13 |
The Trustees Of The University Of Pennsylvania |
Epigenomic editing and reactivation of targets for the treatment of Fragile X syndrome
|
WO2022204549A1
(en)
|
2021-03-25 |
2022-09-29 |
Translate Bio, Inc. |
Optimized nucleotide sequences encoding the extracellular domain of human ace2 protein or a portion thereof
|
WO2022207652A1
(en)
|
2021-03-29 |
2022-10-06 |
Scirhom Gmbh |
Methods of treatment using protein binders to irhom2 epitopes
|
WO2022214664A1
(en)
|
2021-04-09 |
2022-10-13 |
Philogen S.P.A. |
Improved interferon-gamma mutant
|
EP4326338A1
(en)
|
2021-04-19 |
2024-02-28 |
Translate Bio, Inc. |
Improved compositions for delivery of mrna
|
CA3173245A1
(en)
|
2021-04-22 |
2022-10-22 |
James Jefferson Smith |
Engineered meganucleases that target human mitochondrial genomes
|
JP2024517655A
(ja)
|
2021-04-22 |
2024-04-23 |
プレシジョン バイオサイエンシズ,インク. |
ヒトのミトコンドリアゲノムを標的とする操作されたメガヌクレアーゼ
|
AU2022264425A1
(en)
|
2021-04-29 |
2023-12-14 |
Translate Bio, Inc. |
Methods for measuring poly a tail length
|
EP4330391A1
(en)
*
|
2021-04-30 |
2024-03-06 |
The Trustees of the University of Pennsylvania |
Compositions and methods for targeting lipid nanoparticle therapeutics to stem cells
|
WO2022234003A1
(en)
|
2021-05-07 |
2022-11-10 |
Avacta Life Sciences Limited |
Cd33 binding polypeptides with stefin a protein
|
EP4334330A1
(en)
|
2021-05-07 |
2024-03-13 |
Helix Nanotechnologies, Inc. |
Modified ribonucleic acids and uses thereof
|
WO2022261206A1
(en)
|
2021-06-09 |
2022-12-15 |
Icahn School Of Medicine At Mount Sinai |
Gene combination as a broad spectrum antiviral
|
CN117881395A
(zh)
|
2021-07-01 |
2024-04-12 |
翻译生物公司 |
用于递送mRNA的组合物
|
AU2022301302A1
(en)
|
2021-07-01 |
2024-01-25 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
WO2023010133A2
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
AU2022318664A1
(en)
|
2021-07-30 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
WO2023023487A1
(en)
|
2021-08-16 |
2023-02-23 |
Translate Bio, Inc. |
Screening codon-optimized nucleotide sequences
|
WO2023025303A1
(zh)
|
2021-08-26 |
2023-03-02 |
上海君实生物医药科技股份有限公司 |
抗cldn-18.2抗体药物偶联物及其用途
|
TW202332694A
(zh)
|
2021-10-07 |
2023-08-16 |
英商阿凡克塔生命科學公司 |
血清半衰期延長之pd-l1結合多肽
|
WO2023057567A1
(en)
|
2021-10-07 |
2023-04-13 |
Avacta Life Sciences Limited |
Pd-l1 binding affimers
|
CA3235185A1
(en)
|
2021-10-19 |
2023-04-27 |
Cassandra GORSUCH |
Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
|
WO2023070002A2
(en)
|
2021-10-19 |
2023-04-27 |
Precision Biosciences, Inc. |
Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency
|
WO2023068931A1
(en)
|
2021-10-21 |
2023-04-27 |
Curevac Netherlands B.V. |
Cancer neoantigens
|
WO2023067125A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4285933A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4286004A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
EP4169534A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4285932A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4286003A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
WO2023067123A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4186528A1
(en)
|
2021-11-30 |
2023-05-31 |
BioNTech SE |
Oligosaccharide complexes and uses
|
EP4169580A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
EP4286394A1
(en)
|
2022-05-30 |
2023-12-06 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
WO2023067121A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
EP4169578A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
EP4169579A1
(en)
|
2021-10-22 |
2023-04-26 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
WO2023067126A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Oligosaccharide compounds and complexes
|
WO2023067124A1
(en)
|
2021-10-22 |
2023-04-27 |
BioNTech SE |
Disulfide oligosaccharide compounds and complexes
|
WO2023081767A1
(en)
|
2021-11-05 |
2023-05-11 |
Precision Biosciences, Inc. |
Methods for immunotherapy
|
WO2023083434A1
(en)
*
|
2021-11-09 |
2023-05-19 |
BioNTech SE |
Rna encoding peptidoglycan hydrolase and use thereof for treating bacterial infection
|
WO2023086893A1
(en)
|
2021-11-10 |
2023-05-19 |
Translate Bio, Inc. |
Composition and methods for treatment of primary ciliary dyskinesia
|
WO2023107954A1
(en)
|
2021-12-08 |
2023-06-15 |
Dragonfly Therapeutics, Inc. |
Antibodies targeting 5t4 and uses thereof
|
EP4202045A1
(en)
|
2021-12-22 |
2023-06-28 |
Universität Hamburg |
Synthetic transfer rna with modified nucleotides
|
US20230220100A1
(en)
|
2022-01-10 |
2023-07-13 |
Regeneron Pharmaceuticals, Inc. |
Bbb-targeted gaa delivered as gene therapy treats cns and muscle in pompe disease model mice
|
WO2023183921A2
(en)
|
2022-03-24 |
2023-09-28 |
Nature's Toolbox, Inc. |
Methods and compositions for the enzymatic production of pseudouridine triphosphate
|
WO2023218243A1
(en)
|
2022-05-12 |
2023-11-16 |
Avacta Life Sciences Limited |
Lag-3/pd-l1 binding fusion proteins
|
WO2023232747A1
(en)
|
2022-05-30 |
2023-12-07 |
BioNTech SE |
Complexes for delivery of nucleic acids
|
WO2023240076A1
(en)
|
2022-06-07 |
2023-12-14 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
WO2023240074A1
(en)
|
2022-06-07 |
2023-12-14 |
Scribe Therapeutics Inc. |
Compositions and methods for the targeting of pcsk9
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
WO2024002985A1
(en)
|
2022-06-26 |
2024-01-04 |
BioNTech SE |
Coronavirus vaccine
|
WO2024007020A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics, Inc. |
Combination of engineered natural killer (nk) cells and antibody therapy and related methods
|
WO2024015729A1
(en)
|
2022-07-11 |
2024-01-18 |
Icahn School Of Medicine At Mount Sinai |
Regulatory system for expression of a gene of interest in a target cell and method of use thereof
|
WO2024015881A2
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for targeted transcriptional activation
|
WO2024023246A1
(en)
|
2022-07-28 |
2024-02-01 |
Philogen S.P.A. |
Antibody binding to pd1
|
WO2024033362A1
(en)
|
2022-08-08 |
2024-02-15 |
Atb Therapeutics |
Humanized antibodies against cd79b
|
US20240067969A1
(en)
|
2022-08-19 |
2024-02-29 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for regulation of hepatitis b virus through targeted gene repression
|
AU2023274159A1
(en)
|
2022-09-07 |
2024-03-21 |
Eyegene Inc. |
COMPOSITION FOR IN-VIVO DELIVERING mRNA CONTAINING MODIFIED NUCLEOTIDE
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
WO2024064732A2
(en)
|
2022-09-20 |
2024-03-28 |
Visterra, Inc. |
Treatment of complement mediated diseases and disorders with c3b-antibodies
|
WO2024068674A1
(en)
|
2022-09-26 |
2024-04-04 |
BioNTech SE |
Nucleic acid complexes and uses thereof
|
WO2024086827A2
(en)
|
2022-10-20 |
2024-04-25 |
Repertoire Immune Medicines, Inc. |
Cd8 t cell targeted il2
|
WO2024084462A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Nucleic acid complexes and uses thereof
|